BeOne Medicines officer plans sale of 15,000 ADS
BeOne Medicines Ltd. (ONC) received a notice on Form 144 indicating that officer Xiaobin Wu intends to sell up to 15,000 ADS of BeOne Medicines.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BeOne Medicines Ltd. (ONC) received a notice on Form 144 indicating that officer Xiaobin Wu intends to sell up to 15,000 ADS of BeOne Medicines. The ADS were acquired upon the vesting of restricted stock units during the period from 06/05/2022 through 06/05/2023.
The proposed ADS sale is listed for execution through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with a noted date of 08/25/2026. The notice also reports that, during the past three months, Xiaobin Wu sold BeOne common shares in three transactions: 626 shares for $163,512.26 on 06/11/2026, 1,357 shares for $361,996.85 on 06/16/2026, and 1,292 shares for $356,926.89 on 06/23/2026.
Key Figures
Key Terms
Rule 144 regulatory
restricted stock units financial
ADS financial
Form 144 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing disclose for BeOne Medicines Ltd. (ONC)?
How many BeOne Medicines (ONC) ADS are planned to be sold under this Form 144?
When were the restricted stock units for the planned BeOne (ONC) ADS sale acquired?
On which market are the BeOne Medicines (ONC) ADS in this Form 144 listed?
Who is the insider named in the BeOne Medicines (ONC) Form 144 filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.